Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation

55Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: To identify the role of metformin in cardiac hypertrophy and investigate the possible mechanism underlying this effect. Methods: Wild type and AMPKα2 knockout (AMPKα2-/-) littermates were subjected to left ventricular pressure overload caused by transverse aortic constriction. After administration of metformin (200 mgkg-1 d -1) for 6 weeks, the degree of cardiac hypertrophy was evaluated using echocardiography and anatomic and histological methods. The antihypertrophic mechanism of metformin was analyzed using Western blotting. Results: Metformin significantly attenuated cardiac hypertrophy induced by pressure overload in wild type mice, but the antihypertrophic actions of metformin were ablated in AMPKα2-/- mice. Furthermore, metformin suppressed the phosphorylation of Akt/protein kinase B (AKT) and mammalian target of rapamycin (mTOR) in response to pressure overload in wild type mice, but not in AMPKα2-/- mice. Conclusion: Long-term administration of metformin may attenuate cardiac hypertrophy induced by pressure overload in nondiabetic mice, and this attenuation is highly dependent on AMPK activation. These findings may provide a potential therapy for patients at risk of developing pathological cardiac hypertrophy. © 2011 CPS and SIMM All rights reserved.

Cite

CITATION STYLE

APA

Fu, Y. N., Xiao, H., Ma, X. W., Jiang, S. Y., Xu, M., & Zhang, Y. Y. (2011). Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta Pharmacologica Sinica, 32(7), 879–887. https://doi.org/10.1038/aps.2010.229

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free